EHI
Eagle Health Investments Portfolio holdings
AUM
$405M
This Quarter Return
+16.32%
1 Year Return
+14.19%
3 Year Return
+134.25%
5 Year Return
–
10 Year Return
–
AUM
$525M
AUM Growth
+$525M
(+6.6%)
Cap. Flow
-$18.8M
Cap. Flow
% of AUM
-3.58%
Top 10 Holdings %
Top 10 Hldgs %
70.89%
Holding
28
New
5
Increased
5
Reduced
9
Closed
1
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$14M |
| 2 |
Guardant Health
GH
|
$12.6M |
| 3 |
Exact Sciences
EXAS
|
$8.36M |
| 4 |
10x Genomics
TXG
|
$5.07M |
| 5 |
Werewolf Therapeutics
HOWL
|
$4.54M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$13.2M |
| 2 |
IQVIA
IQV
|
$13.1M |
| 3 |
Sarepta Therapeutics
SRPT
|
$11.1M |
| 4 |
Danaher
DHR
|
$11M |
| 5 |
Adaptive Biotechnologies
ADPT
|
$5.95M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $57.9M | 10.75% | 632,714 -58,148 | -8% | -$5.32M |
|
2
Icon
ICLR
$13.8B
| $50.3M | 9.34% | 149,590 -15,510 | -9% | -$5.21M |
|
3
Illumina
ILMN
$15.8B
| $43.8M | 8.13% | 318,754 | – | – |
|
4
United Therapeutics
UTHR
$13.8B
| $41.2M | 7.66% | 179,499 +8,661 | +5% | +$1.99M |
|
5
DexCom
DXCM
$29.5B
| $39.5M | 7.34% | 284,918 -24,400 | -8% | -$3.38M |
|
6
argenx
ARGX
$43.6B
| $33.3M | 6.19% | 84,590 | – | – |
|
|
7
IQVIA
IQV
$32.4B
| $30.8M | 5.73% | 121,895 -51,700 | -30% | -$13.1M |
|
|
8
Danaher
DHR
$147B
| $28.4M | 5.27% | 113,685 -44,100 | -28% | -$11M |
|
9
Inspire Medical Systems
INSP
$2.77B
| $26.2M | 4.88% | 122,203 +8,700 | +8% | +$1.87M |
|
10
Transmedics
TMDX
$3.92B
| $20.6M | 3.83% | 278,655 -36,200 | -11% | -$2.68M |
|
11
Procept Biorobotics
PRCT
$2.23B
| $16.7M | 3.1% | 337,218 | – | – |
|
|
12
Guardant Health
GH
$8.41B
| $15.1M | 2.8% | 730,209 +610,100 | +508% | +$12.6M |
|
13
4D Molecular Therapeutics
FDMT
$288M
| $14.7M | 2.74% | 462,911 +25,000 | +6% | +$797K |
|
14
Intuitive Surgical
ISRG
$170B
| $14.2M | 2.64% | 35,590 -7,800 | -18% | -$3.11M |
|
|
15
Ultragenyx Pharmaceutical
RARE
$2.89B
| $14M | 2.6% | +299,700 | New | +$14M |
|
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $13.4M | 2.48% | 103,256 -86,100 | -45% | -$11.1M |
|
|
FUSN
17
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $12.4M | 2.3% | 579,769 | – | – |
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $9.67M | 1.8% | 330,830 | – | – |
|
|
19
Exact Sciences
EXAS
$8.98B
| $8.36M | 1.55% | +121,000 | New | +$8.36M |
|
20
Pacific Biosciences
PACB
$393M
| $8.13M | 1.51% | 2,167,021 +644,300 | +42% | +$2.42M |
|
|
21
Alnylam Pharmaceuticals
ALNY
$58.5B
| $7.23M | 1.34% | 48,356 -88,400 | -65% | -$13.2M |
|
|
22
10x Genomics
TXG
$1.74B
| $5.07M | 0.94% | +135,059 | New | +$5.07M |
|
|
23
Werewolf Therapeutics
HOWL
$59.9M
| $4.54M | 0.84% | +700,000 | New | +$4.54M |
|
24
Viking Therapeutics
VKTX
$3.04B
| $3.69M | 0.69% | +45,000 | New | +$3.69M |
|
25
Immunocore
IMCR
$1.62B
| $3.01M | 0.56% | 46,300 | – | – |
|